Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 7/20 | 0.73 |
| ▸ | HTR7 | P34969 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | STS | P08842 | 4/20 | 0.58 |
| ▸ | RARB | P10826 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9626903 | 1.00 | HSD17B3 (0.73) | HSD17B3HTR7TP53TSHRL3MBTL1 | |
| SCHEMBL9625875 | 1.00 | HSD17B3 (0.73) | HSD17B3HTR7TP53TSHRL3MBTL1 | |
| SCHEMBL9625683 | 1.00 | HSD17B3 (0.73) | HSD17B3HTR7TP53TSHRL3MBTL1 | |
| SCHEMBL9625687 | 1.00 | HSD17B3 (0.73) | HSD17B3HTR7TP53TSHRL3MBTL1 | |
| SCHEMBL9626892 | 1.00 | HSD17B3 (0.73) | HSD17B3HTR7TP53TSHRL3MBTL1 | |
| SCHEMBL9440276 | 1.00 | HSD17B3 (0.73) | HSD17B3HTR7TP53TSHRL3MBTL1 | |
| SCHEMBL9625547 | 0.98 | HSD17B3 (0.72) | HSD17B3HTR7TP53TSHRL3MBTL1 | |
| SCHEMBL9346532 | 0.95 | HSD17B3 (0.67) | HSD17B3HTR7L3MBTL1MAPTRARB | |
| SCHEMBL5456494 | 0.92 | HSD17B3 (0.71) | HSD17B3HTR7TP53TSHRL3MBTL1 | |
| SCHEMBL13085847 | 0.92 | HSD17B3 (0.85) | HSD17B3HTR7L3MBTL1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20230205083-A1 | SALT COMPOUND, RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-06-29 | — | — | US | disclosed |
| US-20230205083-A1 | SALT COMPOUND, RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-06-29 | — | — | US | disclosed |
| US-20080319074-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-12-25 | — | — | US | disclosed |
| EP-0304359-B1 | OPTICALLY ACTIVE COMPOUND | Showa Shell Sekiyu Kabushiki Kaisha (JP) | 1992-05-06 | — | — | EP | disclosed |
| US-4946989-A | ELECTRIC INDICATIVE ELEMENT OF LIQUID CRYSTALS | SHOWA SHELL SEKIYU KABUSHIKI KAISHA (JP) | 1990-08-07 | — | — | US | disclosed |
| EP-0304359-A1 | Optically active compound | Showa Shell Sekiyu Kabushiki Kaisha (JP) | 1989-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319074-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | HSD17B3 803/4885HTR7 498/4885TP53 3986/4885 |
| US-20230205083-A1 | SALT COMPOUND, RESIST COMPOSITION AND PATTERNING PROCESS | SLC6A9, SLC6A5, REN | HSD17B3 631/4885HTR7 4725/4885TP53 4795/4885 |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | HSD17B3 2796/4885HTR7 219/4885TP53 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.